Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Moderna Makes Major mRNA Commitment To UK

$1bn Investment, According To Health Secretary

Executive Summary

The US biotech major has unveiled plans to open a new research and manufacturing center in the UK, which signals the start of detailed talks with the government about establishing a long-term partnership.

You may also be interested in...



Merck KGaA Exec On Gearing For mRNA Prime Time, De-Risking Manufacturing

Benoit Opsomer, vice-president and head of bioprocessing, Asia Pacific, Merck Life Science, explains how recent targeted CDMO buyouts put the German group in pole position with services across the mRNA value chain, even as it supports global players such as BioNTech. Striking multi-country expansion of manufacturing footprint, including in China, is also underway amid rising demand for biopharma single-use assemblies.

Merck KGaA Exec On Gearing For mRNA Prime Time, De-Risking Manufacturing

Benoit Opsomer, vice-president and head of bioprocessing, Asia Pacific, Merck Life Science, tells Scrip in an interview how recent targeted CDMO buyouts put the German group in pole position with services across the mRNA value chain, even as it supports global players such as BioNTech. Striking multi-country expansion of manufacturing footprint, including in China, is also underway amid rising demand for biopharma single-use assemblies.

Next-Gen Vaccine Makers Want Up-Front Discussions With US FDA To Expedite Development

Early conversations on clinical trial endpoints were particularly helpful in developing Comirnaty, a Pfizer executive said. Whether sponsors can continue to get such discussions may go a long way in determining whether a new generation of products is developed.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146594

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel